OCMS Bio

OCMS Bio is a private antibody discovery and engineering company developing therapeutic monoclonal antibodies and licensing its proprietary screening technology. The company’s core platform, On-Cell mAb Screening (OCMS), uses high-throughput mammalian cell-based, function-first screening to identify and optimize antibodies while preserving native heavy-light chain pairing. OCMS Bio applies this platform to both internal therapeutic programs and partner-enabled discovery efforts, with a preclinical pipeline spanning infectious disease, oncology, autoimmune, metabolic, and rare disease applications. Its lead disclosed asset is OB2401, an anti-RSV prophylactic antibody reported by the company to have outperformed existing alternatives in animal studies. The company is headquartered in King of Prussia, Pennsylvania and appears focused on advancing best-in-class antibody candidates toward clinical development.